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1 Introduction
On February 16, 2015 I was asked by Vice President Prof. Schwarzenegger of University of
Zurich to provide a methodological assessment of two working papers by Prof. Kaul and Prof.
Wolf on the e↵ect of plain packaging on smoking prevalence in Australia and the criticism
raised against these working papers by OxyRomandie.
The materials on which I base my assessment include:
• Working paper no. 149 on “The (Possible) E↵ect of Plain Packaging on the Smoking
Prevalence of Minors in Australia: A Trend Analysis” by Ashok Kaul and Michael Wolf
(Kaul and Wolf 2014b).
• Working paper no. 165 on “The (Possible) E↵ect of Plain Packaging on Smoking Preva-
lence in Australia: A Trend Analysis” by Ashok Kaul and Michael Wolf (Kaul and Wolf
2014a).
• Letter by Pascal A. Diethelm on behalf of OxyRomandie to the President of University
of Zurich, including the annex “Errors and issues with Kaul and Wolf’s two working
papers on tobacco plain packaging in Australia”, dated January 29, 2015 (provided by
Prof. Schwarzenegger).
• Public reply to the letter of Pascal A. Diethelm, including a reply to the annex of the
letter of Pascal A. Diethelm, by Ashok Kaul and Michael Wolf, dated February 11, 2015
(provided by Prof. Schwarzenegger).
• Letter by Pascal A. Diethelm on behalf of OxyRomandie to the President of University
of Zurich, including the document “Comments on Kaul and Wolf’s reply to our Annex”,
dated February 19, 2015 (provided by Prof. Schwarzenegger).
• Forthcoming comment on the “Use and abuse of statistics in tobacco industry-funded
research on standardised packaging” by Laverty, Diethelm, Hopkins, Watt and Mckee
(Laverty et al. forthcoming) (provided by Prof. Schwarzenegger).
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• Monthly data on sample sizes and smoking prevalences, January 2001 to December 2013,
for minors and adults, as displayed in Figures 1 and 2 in Kaul and Wolf (2014a,b) (pro-
vided by Prof. Schwarzenegger).
Prof. Schwarzenegger o↵ered reimbursement of my services at standard rates by my university
for external services (capped at a total of CHF 8000.-), which I accepted. Furthermore, I agreed
with Prof. Schwarzenegger that my report will be made public. I hereby confirm that I have no
commitments to tobacco industry, nor do I have commitments to anti-tobacco institutions such
as OxyRomandie. Moreover, apart from this report, I have no commitments to the University
of Zurich.
Below I will first comment on the potential of the data used by Kaul and Wolf (2014a,b) for
identifying causal e↵ects. I will then provide a reanalysis of the data. Based on this reanalysis
and my reading of the above documents, I will then comment on the criticism raised by Oxy-
Romandie against the working papers by Kaul and Wolf. I will conclude my report with some
remarks on whether I think the working papers should be retracted or not.
2 General remarks on the potential of the given data to identify a causal e↵ect of plain
packaging
In their working papers, Kaul and Wolf analyze monthly population survey data on smoking
prevalence of adults and minors in Australia.1 The time span covers 13 years from January
2001 to December 2013. Plain packaging, according to Kaul an Wolf, was introduced in De-
cember 2012, so that there are 143 months of pre-treatment observations and 13 months of
treatment-period observations (assuming that plain packaging, the treatment, was introduced
on December 1).
In terms of experimental-design language this is called an interrupted time-series design
without control group. It is a quasi-experimental design as there is no randomization of the
treatment. In general, it is di cult to draw causal conclusions from such a design, as it remains
1The data appear to stem from weekly surveys, but Kaul and Wolf base their analyses on monthly aggregates.
It is not known to me whether Kaul and Wolf had access to the individual level weekly data or only to the monthly
aggregates.
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unknown how the counter-factual time trend would have looked. Kaul andWolf assume a linear
time trend and hence base their analyses on a linear fit to the pre-treatment data.2 Deviations
from the extrapolation of the linear fit into the treatment period are then used to identify the
e↵ect of the treatment.3
The assumption behind such an approach is that the time trend would have continued in
the same linear fashion as in the pre-treatment period if there had been no treatment. The
problem is that it is hard to find truly convincing arguments for why this should be the case
(no such arguments are o↵ered by Kaul and Wolf). As argued in the paper by Laverty et al.
(forthcoming) it may be equally plausible that the trend would level o↵ (e.g. because the trend
has to level o↵ naturally once we get close to zero or because the pre-treatment declines were
caused by a series of other tobacco control treatments), or that the trend would accelerate (e.g.
due to business cycles or other factors that might influence tobacco consumption). The point
is: we simply do not know how the trend would have been like without the treatment.
A more meaningful design would be an interrupted time-series with control group or
di↵erence-in-di↵erences. For example, such a design could be realized if the treatment were
implemented only in certain states or districts, but not in others, so that the states or districts
without treatment could be used to identify the baseline trend (the treatment e↵ect is then given
as the di↵erence between the trend in the control group and the trend in the treatment group).
Even though such a design would still be quasi-experimental (i.e. no randomization), one could
certainly make more credible causal inferences with such a design than using a simple time-
series. Such a pseudo-control group could be considered a reasonable counterfactual if the
pre-treatment trends and other significant factors (e.g. business cycles) were similar between
the treatment and pseudo-control groups.
2In the paper on minors, Kaul and Wolf use a linear fit based on all data, including the treatment-period
observations. This is problematic because in this case the linear fit will be biased by the treatment e↵ect, resulting
in treatment-period residuals that are biased towards zero. The “robustness check” in Section 3.4 of their paper,
however, suggests that using only pre-treatment observations for the linear fit does not change their conclusions.
In the paper on adults, Kaul and Wolf consistently base the linear fit only on pre-treatment observations.
3Kaul and Wolf also compare the mean of the 12 residuals after December 2012 to the mean of the last 12
residuals before December 2012. A minor issue with this approach is that the pre-treatment residuals will tend to
be underestimated due to the leverage of the pre-treatment observations with respect to the linear fit.
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Of course, the gold standard would be a true randomized experiment with plain packaging
introduced in some regions but not in others (though causal inference can still be limited in such
a design, for example, due to spillover between regions). What I am trying to say is that causal
inference has high demands on research design (and implementation and data quality) and that
the design on which the working papers by Kaul and Wolf are based on is not particularly
strong. Kaul and Wolf cannot be blamed for this as there might have been no better data, but
they could have been more careful in pointing out the weaknesses of their design.
A second aspect, also mentioned in paper by Laverty et al. (forthcoming), is that given the
nature of the treatment and the outcome of interest, a treatment period of one year might be too
short for the e↵ect to fully unfold. Smoking habits are hard to change, especially with “soft”
measures such as plain packaging, and it would be surprising to see a strong and immediate
e↵ect. Such an e↵ect would only be expected if accessibility were suddenly restricted (e.g.
restaurant bans) or if prices suddenly increased dramatically. The argument, I think, is equally
true for existing smokers and those taking up smoking. The idea of plain packaging, as far as I
can see, is to influence consumption behavior by changing the “image” of tobacco brands and
smoking in general. Such an approach probably has a very slow and subtle e↵ect that might not
be observed in just one year. Moreover, although in the meantime we could probably extend
the time-series with additional months, increasing the treatment observation period does not re-
ally help, as the basic design problem discussed above becomes worse the longer the treatment
period. That is, the longer the follow-up, the less convincingly we can argue that the extrapola-
tion of the pre-treatment trend provides a valid estimate of the counterfactual development had
there been no treatment.
This argument about the treatment period being too short is specific to the topic at hand.
It is not a general design issue. Hence, my argument is not based on theoretical reasoning
but on common sense and background knowledge about addiction and human behavior. The
argument appears plausible to me, but others might disagree or might even provide scientific
evidence proving me wrong. I do not claim that my argument is right. But I do think that it is
an issue that might have deserved some discussion in the papers by Kaul and Wolf.
Given that the estimates are based on survey data, other problems might be present. For
example, samples might be non-representative (no specific information on sampling is given
by Kaul and Wolf) and non-response or social-desirability bias or other measurement errors
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might distort the data. Furthermore, the data analyzed by Kaul and Wolf has been aggregated
from individual-level measurements and errors might have been introduced during this process
(e.g. inadequate treatment of missing values).4 From this point on, however, I ignore these
potential problems, assuming that the data reflect unbiased estimates.
Finally, one could potentially verify the study running an identical time trend analysis using
an alternative data set, such as sales figures from tobacco companies or monthly tax revenues
from tobacco sales in addition to survey data.
3 A reanalysis of the data
I use Stata/MP 13.1, revision 19 Dec 2014, for all analyses below.5 Preparation of the data is
as follows:
. import delimited ../Data/prevMinors.txt, delim(" ") varnames(1) clear
(3 vars, 156 obs)
. generate byte sample = 1
. save tobacco, replace
file tobacco.dta saved
. import delimited ../Data/prevAdults.txt, delim(" ") varnames(1) clear
(3 vars, 156 obs)
. generate byte sample = 2
. append using tobacco
. lab def sample 1 "Minors" 2 "Adults"
. lab val sample sample
. lab var sample "Sample (1=minors, 2=adults)"
. lab var month "Month (1=January 2001)"
. forv i = 1/156 {
2. lab def month `i´ "`:di %tmMonCCYY tm(2001m1) + `i´ - 1´", add
3. }
. lab val month month
. lab var observations "Sample size"
. lab var prevalence "Smoking prevalence"
. order sample month
. sort sample month
. save tobacco, replace
file tobacco.dta saved
4It is not entirely clear whether Kaul and Wolf received individual-level data and did the aggregation them-
selves or whether they received pre-aggregated data. If they did have access to the individual-level data, it is
unclear to me why they used WLS on aggregate data instead of directly analyzing the individual-level data. Ana-
lyzing the individual-level data would be interesting as changing sample compositions could be controlled for or
subgroup analyses could be performed.
5User packages “coefplot” (Jann 2014), “estout” (Jann 2005b), and “moremata” (Jann 2005a) are required to
run the code below. In Stata, type “ssc install coefplot”, “ssc install estout”, and “ssc install moremata” to install
the packages.
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. describe
Contains data from tobacco.dta
obs: 312
vars: 4 6 Mar 2015 17:17
size: 4,056
storage display value
variable name type format label variable label
sample byte %8.0g sample Sample (1=minors, 2=adults)
month int %8.0g month Month (1=January 2001)
observations int %8.0g Sample size
prevalence double %10.0g Smoking prevalence
Sorted by: sample month
3.1 Choice of baseline model
As mentioned above, Kaul and Wolf (2014a,b) use a two-step approach to analyze the data by
first fitting a linear model to the pre-treatment data6 and then investigating the (out of sam-
ple) residuals for the treatment period. This is acceptable, but in my opinion a simpler and
more straightforward approach would be to directly estimate the treatment e↵ect by including
additional parameters in the model. Irrespective of whether we use a two-step or a one-step
approach, however, we first have to choose a suitable baseline model. Kaul and Wolf use a
weighted least-squares model (WLS) based on the aggregate data (where the weights are the
sample sizes). Using WLS instead of ordinary least-squares (OLS) is appropriate because this
yields essentially the same results as applying OLS to the individual data. This is illustrated by
the following analysis using the data on minors (the results of the WLS model are identical to
the results in Section 3.4 in Kaul and Wolf 2014b):
. use tobacco
. quietly keep if sample==1
. regress prevalence month if month<144 [aw=observations]
(sum of wgt is 3.8564e+04)
Source SS df MS Number of obs = 143
F( 1, 141) = 90.14
Model .030136654 1 .030136654 Prob > F = 0.0000
Residual .047142285 141 .000334342 R-squared = 0.3900
Adj R-squared = 0.3856
Total .07727894 142 .000544218 Root MSE = .01829
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0003559 .0000375 -9.49 0.000 -.00043 -.0002818
_cons .114086 .0028709 39.74 0.000 .1084105 .1197615
. expand observations
(41282 observations created)
6See also footnote 2.
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. sort sample month
. by sample month: gen byte smokes = (_n<= round(observations*prevalence))
. regress smokes month if month<144
Source SS df MS Number of obs = 38564
F( 1, 38562) = 98.48
Model 8.12720289 1 8.12720289 Prob > F = 0.0000
Residual 3182.40127 38562 .082526873 R-squared = 0.0025
Adj R-squared = 0.0025
Total 3190.52847 38563 .082735484 Root MSE = .28727
smokes Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0003559 .0000359 -9.92 0.000 -.0004262 -.0002856
_cons .114086 .0027466 41.54 0.000 .1087026 .1194694
We can see that WLS based on aggregated data and OLS based on the expanded individual-
level data (which can be reconstructed here because the dependent variable is binary) yield
identical point estimates and only di↵er trivially in standard errors. Given that the dependent
variable is dichotomous, however, a more appropriate model for the data might be logistic re-
gression (or Probit regression, which yields almost identical results as logistic regression, apart
from scaling). Logistic regression, for example, has the advantage that e↵ects level o↵ once
getting close to zero or one by construction, so that predictions outside 0 to 1 are not possible.
Logistic regression can be estimated directly from the aggregate data (logistic regression for
grouped data), yielding identical results as a standard individual-level Logit model. The output
below shows the results and also provides a graph comparing the Logit fit and the WLS fit.
. use tobacco
. quietly keep if sample==1
. generate smokers = round(observations*prevalence)
. blogit smokers observations month if month<144
Logistic regression for grouped data Number of obs = 38564
LR chi2(1) = 99.77
Prob > chi2 = 0.0000
Log likelihood = -11707.726 Pseudo R2 = 0.0042
_outcome Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.0044098 .0004462 -9.88 0.000 -.0052844 -.0035352
_cons -2.028496 .0317162 -63.96 0.000 -2.090659 -1.966334
. predict y_logit, pr
. generate r2_logit = (prevalence - y_logit)ˆ2
. qui regress prevalence month if month<144 [aw=observations]
. predict y_WLS
(option xb assumed; fitted values)
. generate r2_WLS = (prevalence - y_WLS)ˆ2
. summarize r2_* if month<144 [aw=observations]
Variable Obs Weight Mean Std. Dev. Min Max
r2_logit 143 38564 .0003292 .0005008 3.87e-09 .0030856
r2_WLS 143 38564 .0003297 .0005065 1.24e-09 .003152
. two (line prev month, lc(*.6)) ///
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> (lowess prev month, lw(*1.5) psty(p3)) ///
> (line y_WLS month if month<144, lw(*1.5) psty(p2)) ///
> (line y_logit month if month<144, lw(*1.5) psty(p4)) ///
> (line y_WLS month if month>=144, lw(*1.5) psty(p2) lp(shortdash)) ///
> (line y_logit month if month>=144, lw(*1.5) psty(p4) lp(shortdash)) ///
> , legend(order(3 "WLS" 4 "Logit" 2 "Lowess") rows(1)) ///
> xti("") yti(Prevalence) xline(143.5) ylab(.025(.025).15, angle(hor)) ///
> xlab(1(36)145, valuelabel)
.025
.05
.075
.1
.125
.15
Pr
ev
ale
nc
e
Jan2001 Jan2004 Jan2007 Jan2010 Jan2013
WLS Logit Lowess
The two fits are almost identical, although the Logit fit is slightly curved. Also in terms of
average squared residuals (weighted by sample size) the two fits are very similar (with slightly
smaller squared residuals from the Logit model; see the second table in the output above).
For comparison, a standard Lowess fit (unweighted7) is also included in the graph. It can be
seen that the WLS fit and the Logit fit closely resemble the Lowess fit across most of the pre-
treatment period.8 From these results I conclude that both WLS and Logit with a simple linear
7Lowess in Stata does not support weights. A weighted local polynomial fit of degree 1 (linear) yields a very
similar result if using a comparable bandwidth (not shown)
8Note that the Lowess fit uses all data including the treatment-period observations and that such nonparametric
estimators are a↵ected by boundary problems, hence the deviation at the beginning of the observation period and
especially in the treatment period. Whether the drop of the curve in the treatment period is systematic will be
evaluated below.
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time-trend parameter provide a good approximation of the baseline trend in the pre-treatment
period.
The next output and graph show a similar exercise for the adult data. An issue with the
adult data is that a linear model does not fit the pre-treatment period very well. For example, a
quadratic model indicates curvature (significant coe cient of month squared in the first table
of the output below). Based on graphical inspection of a nonparametric smooth, Kaul and Wolf
(2014a) decided to use only observations from July 2004 on to estimate the baseline trend in the
pre-treatment period. For now I follow this approach, though later I consider how this decision
impacted results.
. use tobacco
. quietly keep if sample==2
. generate monthsq = monthˆ2
. regress prevalence month monthsq if month<144 [aw=observations]
(sum of wgt is 6.5227e+05)
Source SS df MS Number of obs = 143
F( 2, 140) = 317.43
Model .036153612 2 .018076806 Prob > F = 0.0000
Residual .007972556 140 .000056947 R-squared = 0.8193
Adj R-squared = 0.8167
Total .044126168 142 .000310748 Root MSE = .00755
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0002346 .0000611 -3.84 0.000 -.0003555 -.0001138
monthsq -1.04e-06 4.13e-07 -2.52 0.013 -1.86e-06 -2.26e-07
_cons .2419662 .0018901 128.02 0.000 .2382293 .245703
. regress prevalence month if inrange(month,43,143) [aw=observations]
(sum of wgt is 4.5396e+05)
Source SS df MS Number of obs = 101
F( 1, 99) = 301.72
Model .017559625 1 .017559625 Prob > F = 0.0000
Residual .005761653 99 .000058199 R-squared = 0.7529
Adj R-squared = 0.7504
Total .023321278 100 .000233213 Root MSE = .00763
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0004494 .0000259 -17.37 0.000 -.0005008 -.0003981
_cons .2523039 .0024979 101.01 0.000 .2473475 .2572602
. predict y_WLS
(option xb assumed; fitted values)
. generate r2_WLS = (prevalence - y_WLS)ˆ2
. generate smokers = round(observations*prevalence)
. blogit smokers observations month if inrange(month,43,143)
Logistic regression for grouped data Number of obs = 453961
LR chi2(1) = 474.74
Prob > chi2 = 0.0000
Log likelihood = -233659.53 Pseudo R2 = 0.0010
_outcome Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.0027059 .0001243 -21.76 0.000 -.0029496 -.0024622
_cons -1.072061 .0118411 -90.54 0.000 -1.095269 -1.048853
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. predict y_logit, pr
. generate r2_logit = (prevalence - y_logit)ˆ2
. summarize r2_* if inrange(month,43,143) [aw=observations]
Variable Obs Weight Mean Std. Dev. Min Max
r2_WLS 101 453961 .000057 .0000735 8.90e-08 .000374
r2_logit 101 453961 .0000569 .0000732 6.08e-09 .0003838
. two (line prev month, lc(*.6)) ///
> (lowess prev month, lw(*1.5) psty(p3)) ///
> (line y_WLS month if inrange(month,43,143), lw(*1.5) psty(p2)) ///
> (line y_logit month if inrange(month,43,143), lw(*1.5) psty(p4)) ///
> (line y_WLS month if month>=144, lw(*1.5) psty(p2) lp(shortdash)) ///
> (line y_logit month if month>=144, lw(*1.5) psty(p4) lp(shortdash)) ///
> (line y_WLS month if month<43, lw(*1.5) psty(p2) lp(shortdash)) ///
> (line y_logit month if month<43, lw(*1.5) psty(p4) lp(shortdash)) ///
> , legend(order(3 "WLS" 4 "Logit" 2 "Lowess") rows(1)) ///
> xti("") yti(Prevalence) xline(42.5 143.5) ylab(.17(.02).25, angle(hor)) ///
> xlab(1(36)145, valuelabel)
.17
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.21
.23
.25
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WLS Logit Lowess
Again, both WLS and Logit provide a very good approximation of the time trend, at least in
the second part of the pre-treatment observation period (from around 2006). In terms of squared
residuals both fits perform equally well (again with a tiny advantage for the Logit model; see
fourth table in the output above). The WLS results (second table in the output above) are
identical to the results reported by Kaul and Wolf (2014a, Equation 3.3).
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3.2 Treatment e↵ect estimation
3.2.1 Immediate (time-constant) treatment e↵ect
The most straightforward approach to estimate the treatment e↵ect of plain packaging is to
apply the above models to all observations and include an indicator variable for the treatment.
The treatment indicator is 0 for observations prior to December 2012 and 1 for observations
from December 2012 on. The coe cient of the treatment indicator provides an estimate of
the treatment e↵ect, modeled as a parallel shift in the trend from December 2012 on (i.e. an
immediate and time-constant treatment e↵ect).9 The results from such a model for minors and
adults are as follows:
. use tobacco
. generate byte treat = month>=144
. generate smokers = round(observations*prevalence)
. preserve
. quietly keep if sample==1 // => minors
. regress prevalence month treat [aw=observations]
(sum of wgt is 4.1438e+04)
Source SS df MS Number of obs = 156
F( 2, 153) = 65.96
Model .043186903 2 .021593452 Prob > F = 0.0000
Residual .050089722 153 .000327384 R-squared = 0.4630
Adj R-squared = 0.4560
Total .093276625 155 .000601785 Root MSE = .01809
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0003558 .0000368 -9.67 0.000 -.0004285 -.0002831
treat -.0051258 .0065024 -0.79 0.432 -.017972 .0077203
_cons .1140834 .0028188 40.47 0.000 .1085145 .1196522
. predict y_WLS
(option xb assumed; fitted values)
. blogit smokers observations month treat
Logistic regression for grouped data Number of obs = 41438
LR chi2(2) = 146.56
Prob > chi2 = 0.0000
Log likelihood = -12325.285 Pseudo R2 = 0.0059
_outcome Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.0044102 .0004461 -9.89 0.000 -.0052846 -.0035358
treat -.1422188 .0925872 -1.54 0.125 -.3236864 .0392488
_cons -2.028472 .0317117 -63.97 0.000 -2.090626 -1.966318
. predict y_logit, pr
. two (line prev month, lc(*.6)) ///
> (line y_WLS month if month<144 , lw(*1.5) psty(p2)) ///
> (line y_logit month if month<144 , lw(*1.5) psty(p4)) ///
9The estimated pre-treatment baseline trend in such a model can be a↵ected by treatment-period observations
because the model is not fully flexible. However, this e↵ect is only minimal in the present case (compare the
models below with the results in Section 3.1).
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> (line y_WLS month if month>=144, lw(*1.5) psty(p2)) ///
> (line y_logit month if month>=144, lw(*1.5) psty(p4)) ///
> if month>=131, legend(order(2 "WLS" 3 "Logit") rows(1)) ///
> xti("") yti(Prevalence) xline(143.5) ylab(.03(.01).08, angle(hor)) ///
> xlab(132(6)156, valuelabel) xoverhangs ti(Minors) nodraw name(minors)
. restore, preserve
. quietly keep if sample==2 & month>=43 // => adults
. regress prevalence month treat [aw=observations]
(sum of wgt is 5.0666e+05)
Source SS df MS Number of obs = 114
F( 2, 111) = 230.95
Model .025753273 2 .012876636 Prob > F = 0.0000
Residual .006188756 111 .000055755 R-squared = 0.8063
Adj R-squared = 0.8028
Total .031942028 113 .000282673 Root MSE = .00747
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0004484 .0000252 -17.82 0.000 -.0004983 -.0003985
treat -.0015422 .0027153 -0.57 0.571 -.0069227 .0038383
_cons .2522081 .0024292 103.82 0.000 .2473946 .2570217
. predict y_WLS
(option xb assumed; fitted values)
. blogit smokers observations month treat
Logistic regression for grouped data Number of obs = 506657
LR chi2(2) = 696.42
Prob > chi2 = 0.0000
Log likelihood = -258774.15 Pseudo R2 = 0.0013
_outcome Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.0027001 .0001242 -21.73 0.000 -.0029435 -.0024566
treat -.0158519 .0139325 -1.14 0.255 -.0431591 .0114553
_cons -1.072587 .0118326 -90.65 0.000 -1.095779 -1.049396
. predict y_logit, pr
. two (line prev month, lc(*.6)) ///
> (line y_WLS month if month<144 , lw(*1.5) psty(p2)) ///
> (line y_logit month if month<144 , lw(*1.5) psty(p4)) ///
> (line y_WLS month if month>=144, lw(*1.5) psty(p2)) ///
> (line y_logit month if month>=144, lw(*1.5) psty(p4)) ///
> if month>=131, legend(order(2 "WLS" 3 "Logit") rows(1)) ///
> xti("") yti(Prevalence) xline(143.5) ylab(.17(.01).20, angle(hor)) ///
> xlab(132(6)156, valuelabel) xoverhangs ti(Adults) nodraw name(adults)
. restore
. graph combine minors adults, imargin(zero)
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For minors the estimated treatment e↵ect is about 0.5 percentage points (the first table in
the output above), for adults the e↵ect is about 0.15 percentage points (the third table in the
output above), but none of these treatment e↵ects are significant (p = 0.432 and p = 0.125
from WLS and Logit for minors; p = 0.571 and p = 0.255 from WLS and Logit for adults).
The graph, zooming in on the last two years of the observation window, illustrates the e↵ect as
a parallel shift of the curves between November and December 2012.
Bound to a strict interpretation of significance tests (employing a usual 5% significance
level), we would conclude from these results that there is no convincing evidence for an e↵ect
of plain packaging on smoking prevalence, neither for minors nor for adults and irrespective of
whether we use two-sided tests or one-sided tests. However, if we employ a more gradual in-
terpretation of statistical results without resorting to strict (and somewhat arbitrary) cuto↵s, we
can acknowledge that the e↵ects at least point in the expected direction.10 For example, using
a one-sided test, the p-value from the logistic regression for minors is p = 0.062, which is not
far from the conventional 5% level. To be fair, results from WLS, and results for adults, where
statistical power is higher due to the larger sample sizes, are considerably less convincing.
10Expected in the sense that the purpose of introducing plain packaging was to reduce smoking prevalence.
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As mentioned above, an issue with the results for adults is that the pre-treatment observa-
tions before July 2004 were excluded due to lack of fit of the linear baseline model. Using July
2004 as cuto↵ is an arbitrary decision that might favor result in one direction or the other. To
evaluate whether the precise location of the cuto↵ a↵ects our conclusions, we can run a series of
models using varying cuto↵s. The following graph shows how the e↵ect evolves if we increase
the cuto↵ in monthly steps from January 2001 (i.e. using all data) to January 2008 (where the
WLS and Logit fits are essentially indistinguishable from the Lowess fit; see Section 3.1):
. use tobacco
. generate byte treat = month>=144
. generate smokers = round(observations*prevalence)
. quietly keep if sample==2
. forv i = 1/85 {
2. qui regress prevalence month treat if month>=`i´ [aw=observations]
3. mat tmp = _b[treat] \ _se[treat] \ e(df_r)
4. qui blogit smokers observations month treat if month>=`i´
5. mat tmp = tmp \ _b[treat] \ _se[treat]
6. mat coln tmp = `i´
7. mat res = nullmat(res), tmp
8. }
. coefplot (mat(res[1]), se(res[2]) drop(43) df(res[3]) ) ///
> (mat(res[1]), se(res[2]) keep(43) df(res[3]) pstyle(p4)), bylabel(WLS) ///
> || (mat(res[4]), se(res[5]) drop(43)) ///
> (mat(res[4]), se(res[5]) keep(43)), bylabel(Logit) ///
> || , at(_coef) ms(o) nooffset levels(95 90) yline(0) ///
> byopts(cols(1) yrescale legend(off)) ///
> xlab(1 "`:lab month 1´" 13 "`:lab month 13´" ///
> 25 "`:lab month 25´" 37 "`:lab month 37´" ///
> 49 "`:lab month 49´" 61 "`:lab month 61´" ///
> 73 "`:lab month 73´" 85 "`:lab month 85´")
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From this graph I conclude that the precise location of the cuto↵ is rather irrelevant. From
July 2004 (highlighted) on there is not much change and all e↵ects are clearly insignificant (the
thin and thick lines depict the 95% and 90% confidence intervals, respectively; if the thin line
does not cross the red reference line, then the e↵ect is significantly di↵erent from zero at the 5%
level using a two-sided test; if the thick line does not cross the red reference line, then the e↵ect
is significantly negative at the 5% level using a one-sided test). To the left of July 2004 the
e↵ect systematically grows and eventually becomes significant. However, in this region there
is considerable misfit of the linear model (see Section 3.1 above), which inflates the treatment
e↵ect estimate.
3.2.2 Time-varying treatment e↵ect
In the last section I used a model that assumes an immediate treatment e↵ect that is constant
across months. The assumption might not be particularly realistic, but with respect to statistical
power the assumption is favorable because it only introduces one additional parameter. A more
flexible approach would be to use two parameters so that location and slope of the trend can
to change with treatment. This model allows a time-varying treatment e↵ect, with a possible
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initial shock and then a linear increase or decrease of the treatment e↵ect over time. Using such
a model yields the following results:
. use tobacco
. generate byte treat = month>=144
. generate treatmonth = treat * (month - 144)
. generate smokers = round(observations*prevalence)
. preserve
. quietly keep if sample==1 // => minors
. regress prevalence month treat treatmonth [aw=observations]
(sum of wgt is 4.1438e+04)
Source SS df MS Number of obs = 156
F( 3, 152) = 43.69
Model .043187597 3 .014395866 Prob > F = 0.0000
Residual .050089028 152 .000329533 R-squared = 0.4630
Adj R-squared = 0.4524
Total .093276625 155 .000601785 Root MSE = .01815
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0003559 .0000369 -9.64 0.000 -.0004288 -.0002829
treat -.0055249 .0108718 -0.51 0.612 -.0270042 .0159544
treatmonth .00007 .0015261 0.05 0.963 -.0029451 .0030852
_cons .114086 .0028287 40.33 0.000 .1084974 .1196746
. testparm treat treatmonth
( 1) treat = 0
( 2) treatmonth = 0
F( 2, 152) = 0.31
Prob > F = 0.7341
. predict y_WLS
(option xb assumed; fitted values)
. blogit smokers observations month treat treatmonth
Logistic regression for grouped data Number of obs = 41438
LR chi2(3) = 146.56
Prob > chi2 = 0.0000
Log likelihood = -12325.284 Pseudo R2 = 0.0059
_outcome Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.0044098 .0004462 -9.88 0.000 -.0052844 -.0035352
treat -.1363834 .1573283 -0.87 0.386 -.4447413 .1719745
treatmonth -.0010318 .0225153 -0.05 0.963 -.0451609 .0430974
_cons -2.028496 .0317162 -63.96 0.000 -2.090659 -1.966334
. testparm treat treatmonth
( 1) [_outcome]treat = 0
( 2) [_outcome]treatmonth = 0
chi2( 2) = 2.36
Prob > chi2 = 0.3071
. predict y_logit, pr
. two (line prev month, lc(*.6)) ///
> (line y_WLS month if month<144 , lw(*1.5) psty(p2)) ///
> (line y_logit month if month<144 , lw(*1.5) psty(p4)) ///
> (line y_WLS month if month>=144, lw(*1.5) psty(p2)) ///
> (line y_logit month if month>=144, lw(*1.5) psty(p4)) ///
> if month>=131, legend(order(2 "WLS" 3 "Logit") rows(1)) ///
> xti("") yti(Prevalence) xline(143.5) ylab(.03(.01).08, angle(hor)) ///
> xlab(132(6)156, valuelabel) xoverhangs ti(Minors) nodraw name(minors)
. restore, preserve
. quietly keep if sample==2 & month>=43 // => adults
. regress prevalence month treat treatmonth [aw=observations]
(sum of wgt is 5.0666e+05)
Source SS df MS Number of obs = 114
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F( 3, 110) = 154.22
Model .025806291 3 .008602097 Prob > F = 0.0000
Residual .006135737 110 .000055779 R-squared = 0.8079
Adj R-squared = 0.8027
Total .031942028 113 .000282673 Root MSE = .00747
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0004494 .0000252 -17.84 0.000 -.0004994 -.0003995
treat -.0049024 .0043881 -1.12 0.266 -.0135985 .0037937
treatmonth .0005794 .0005943 0.97 0.332 -.0005984 .0017572
_cons .2523039 .0024317 103.76 0.000 .2474848 .2571229
. testparm treat treatmonth
( 1) treat = 0
( 2) treatmonth = 0
F( 2, 110) = 0.64
Prob > F = 0.5311
. predict y_WLS
(option xb assumed; fitted values)
. blogit smokers observations month treat treatmonth
Logistic regression for grouped data Number of obs = 506657
LR chi2(3) = 697.76
Prob > chi2 = 0.0000
Log likelihood = -258773.48 Pseudo R2 = 0.0013
_outcome Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.0027059 .0001243 -21.76 0.000 -.0029496 -.0024622
treat -.0365765 .022708 -1.61 0.107 -.0810834 .0079304
treatmonth .0035737 .0030838 1.16 0.247 -.0024704 .0096179
_cons -1.072061 .0118411 -90.54 0.000 -1.095269 -1.048853
. testparm treat treatmonth
( 1) [_outcome]treat = 0
( 2) [_outcome]treatmonth = 0
chi2( 2) = 2.63
Prob > chi2 = 0.2687
. predict y_logit, pr
. two (line prev month, lc(*.6)) ///
> (line y_WLS month if month<144 , lw(*1.5) psty(p2)) ///
> (line y_logit month if month<144 , lw(*1.5) psty(p4)) ///
> (line y_WLS month if month>=144, lw(*1.5) psty(p2)) ///
> (line y_logit month if month>=144, lw(*1.5) psty(p4)) ///
> if month>=131, legend(order(2 "WLS" 3 "Logit") rows(1)) ///
> xti("") yti(Prevalence) xline(143.5) ylab(.17(.01).20, angle(hor)) ///
> xlab(132(6)156, valuelabel) xoverhangs ti(Adults) nodraw name(adults)
. restore
. graph combine minors adults, imargin(zero)
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The parametrization of the models is such that the main e↵ect of the treatment variable
(the second coe cient in the models) reflects the size of the initial shock in December 2012.
The results for minors are qualitatively similar to the results from the simpler model above
(immediate shift of the curve of about 0.5 percentage points without much change in slope).
Results for adults are such that we have an initial shock of about 0.5 percentage points and then
the e↵ect declines (positive interaction e↵ect). Since the interaction e↵ect is larger in size than
the baseline trend e↵ect, the slope of the trend even turns positive after December 2012. This
is certainly not what Australian authorities would have hoped for. However, note that none of
these e↵ects are significant, neither the initial shock, nor the change in slope, nor both together
using a joint test (see the “testparm” commands in the output).
Overall, the results in this section do not seem to add much additional insight.
3.2.3 Gradual treatment e↵ect
A further option to model the treatment e↵ect is to assume that there is no specific initial shock,
but that the e↵ect gradually builds up over time. This can be implemented, for example, using
a model with linear splines. The following output and graph show the results:
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. use tobacco
. generate treatmonth = cond(month>143, month-143, 0)
. generate smokers = round(observations*prevalence)
. preserve
. quietly keep if sample==1 // => minors
. regress prevalence month treatmonth [aw=observations]
(sum of wgt is 4.1438e+04)
Source SS df MS Number of obs = 156
F( 2, 153) = 65.76
Model .043117457 2 .021558729 Prob > F = 0.0000
Residual .050159168 153 .000327838 R-squared = 0.4623
Adj R-squared = 0.4552
Total .093276625 155 .000601785 Root MSE = .01811
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0003599 .0000358 -10.06 0.000 -.0004306 -.0002893
treatmonth -.0005235 .0008189 -0.64 0.524 -.0021412 .0010942
_cons .1142626 .0027954 40.87 0.000 .10874 .1197852
. lincom month + treatmonth
( 1) month + treatmonth = 0
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
(1) -.0008834 .0008041 -1.10 0.274 -.002472 .0007051
. predict y_WLS
(option xb assumed; fitted values)
. blogit smokers observations month treatmonth
Logistic regression for grouped data Number of obs = 41438
LR chi2(2) = 145.96
Prob > chi2 = 0.0000
Log likelihood = -12325.585 Pseudo R2 = 0.0059
_outcome Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.0044852 .0004358 -10.29 0.000 -.0053394 -.0036309
treatmonth -.0158411 .0119505 -1.33 0.185 -.0392637 .0075816
_cons -2.025471 .0314661 -64.37 0.000 -2.087143 -1.963798
. lincom month + treatmonth
( 1) [_outcome]month + [_outcome]treatmonth = 0
Coef. Std. Err. z P>|z| [95% Conf. Interval]
(1) -.0203262 .0117859 -1.72 0.085 -.0434263 .0027738
. predict y_logit, pr
. two (line prev month, lc(*.6)) ///
> (line y_WLS month, lw(*1.5) psty(p2)) ///
> (line y_logit month, lw(*1.5) psty(p4)) ///
> if month>=131, legend(order(2 "WLS" 3 "Logit") rows(1)) ///
> xti("") yti(Prevalence) xline(143.5) ylab(.03(.01).08, angle(hor)) ///
> xlab(132(6)156, valuelabel) xoverhangs ti(Minors) nodraw name(minors)
. restore, preserve
. quietly keep if sample==2 & month>=43 // => adults
. regress prevalence month treatmonth [aw=observations]
(sum of wgt is 5.0666e+05)
Source SS df MS Number of obs = 114
F( 2, 111) = 230.14
Model .025735581 2 .01286779 Prob > F = 0.0000
Residual .006206448 111 .000055914 R-squared = 0.8057
Adj R-squared = 0.8022
Total .031942028 113 .000282673 Root MSE = .00748
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prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0004569 .0000243 -18.78 0.000 -.0005051 -.0004087
treatmonth .0000241 .0003319 0.07 0.942 -.0006337 .0006818
_cons .2528662 .0023827 106.12 0.000 .2481447 .2575877
. lincom month + treatmonth
( 1) month + treatmonth = 0
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
(1) -.0004329 .0003208 -1.35 0.180 -.0010686 .0002028
. predict y_WLS
(option xb assumed; fitted values)
. blogit smokers observations month treatmonth
Logistic regression for grouped data Number of obs = 506657
LR chi2(2) = 695.22
Prob > chi2 = 0.0000
Log likelihood = -258774.75 Pseudo R2 = 0.0013
_outcome Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.0027573 .0001201 -22.96 0.000 -.0029927 -.0025219
treatmonth -.0005219 .0017073 -0.31 0.760 -.0038682 .0028244
_cons -1.06824 .0115959 -92.12 0.000 -1.090967 -1.045512
. lincom month + treatmonth
( 1) [_outcome]month + [_outcome]treatmonth = 0
Coef. Std. Err. z P>|z| [95% Conf. Interval]
(1) -.0032793 .0016532 -1.98 0.047 -.0065194 -.0000391
. predict y_logit, pr
. two (line prev month, lc(*.6)) ///
> (line y_WLS month, lw(*1.5) psty(p2)) ///
> (line y_logit month, lw(*1.5) psty(p4)) ///
> if month>=131, legend(order(2 "WLS" 3 "Logit") rows(1)) ///
> xti("") yti(Prevalence) xline(143.5) ylab(.17(.01).20, angle(hor)) ///
> xlab(132(6)156, valuelabel) xoverhangs ti(Adults) nodraw name(adults)
. restore
. graph combine minors adults, imargin(zero)
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The results suggest a change in trend for minors with a treatment e↵ect in December 2012
of about 0.05 percentage points that builds up to about 0.6 percentage points until December
2013. The e↵ect, however, is not significant, with p-values of 0.524 and 0.185 for WLS and the
Logit model, respectively (using two-sided tests). Using a one-sided test the change in slope
would be significant in the Logit model at the 10% level. For adults, there is hardly any change
in slope (with p-values of 0.942 and 0.760). In sum, similar to the models with an immediate
treatment e↵ect above, we find some mild evidence for an e↵ect on minors if we are willing to
resort to a loose interpretation of statistical tests.
The results also provide tests against a flat trend (the “lincom” results in the output above).
Here the null hypothesis is that the smoking prevalence remains constant from November 2012
on. For adults, using the Logit model, we can conclude that there was a further significant
decrease in smoking prevalence after November 2012 (using a two-sided test at the 5% level).
For minors, the test based on the Logit model is significant at the 5% level only if we are
willing to employ a one-sided test. The results from the WLS models are less clear with two-
sided p-values of 0.274 and 0.180 for minors and adults, respectively. The fact that we cannot
uniformly reject the hypothesis that there was no further decline in smoking prevalence after
November 2012 raises concerns about statistical power. Based on the amount of treatment-
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period data available it seems to be di cult to reject any reasonable null hypothesis about the
development of smoking prevalence after November 2012.
3.2.4 Monthly treatment e↵ects
More flexible approaches exist to model the treatment e↵ect, but they all need additional pa-
rameters and hence sacrifice statistical power. The most flexible model is one that includes
an additional parameter for each treatment-period month, which is analogous to the two-step
approach followed by Kaul and Wolf (2014a,b). Using such a model I get the following results:
. use tobacco
. clonevar treatmonth = month
. replace treatmonth = 0 if treatmonth<144
(286 real changes made)
. generate smokers = round(observations*prevalence)
. preserve
. quietly keep if sample==1 // => minors
. eststo mWLS: regress prevalence month i.treatmonth [aw=observations]
(sum of wgt is 4.1438e+04)
Source SS df MS Number of obs = 156
F( 14, 141) = 9.56
Model .045415546 14 .003243968 Prob > F = 0.0000
Residual .047861079 141 .00033944 R-squared = 0.4869
Adj R-squared = 0.4359
Total .093276625 155 .000601785 Root MSE = .01842
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0003559 .0000375 -9.49 0.000 -.00043 -.0002818
treatmonth
Dec2012 -.0070456 .019953 -0.35 0.725 -.0464913 .0324
Jan2013 -.019473 .0222739 -0.87 0.383 -.0635071 .024561
Feb2013 .0113415 .0194838 0.58 0.561 -.0271766 .0498596
Mar2013 -.0205735 .0186955 -1.10 0.273 -.0575333 .0163863
Apr2013 -.0033804 .0203613 -0.17 0.868 -.0436332 .0368724
May2013 .020907 .0195403 1.07 0.286 -.0177228 .0595368
Jun2013 .0046803 .0189558 0.25 0.805 -.032794 .0421545
Jul2013 -.0159937 .0193995 -0.82 0.411 -.0543452 .0223579
Aug2013 -.0289045 .0219133 -1.32 0.189 -.0722256 .0144165
Sep2013 -.0008132 .0213365 -0.04 0.970 -.0429941 .0413677
Oct2013 -.0222438 .0221489 -1.00 0.317 -.0660307 .0215431
Nov2013 .0029798 .0210504 0.14 0.888 -.0386355 .0445951
Dec2013 .0057584 .0232658 0.25 0.805 -.0402366 .0517534
_cons .114086 .0028709 39.74 0.000 .1084105 .1197615
. testparm i.treatmonth
( 1) 144.treatmonth = 0
( 2) 145.treatmonth = 0
( 3) 146.treatmonth = 0
( 4) 147.treatmonth = 0
( 5) 148.treatmonth = 0
( 6) 149.treatmonth = 0
( 7) 150.treatmonth = 0
( 8) 151.treatmonth = 0
( 9) 152.treatmonth = 0
(10) 153.treatmonth = 0
(11) 154.treatmonth = 0
(12) 155.treatmonth = 0
24
(13) 156.treatmonth = 0
F( 13, 141) = 0.55
Prob > F = 0.8884
. eststo mLOG: blogit smokers observations month i.treatmonth
Logistic regression for grouped data Number of obs = 41438
LR chi2(14) = 158.01
Prob > chi2 = 0.0000
Log likelihood = -12319.558 Pseudo R2 = 0.0064
_outcome Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.0044098 .0004462 -9.88 0.000 -.0052844 -.0035352
treatmonth
Dec2012 -.1651711 .2884849 -0.57 0.567 -.7305912 .400249
Jan2013 -.4344251 .3638778 -1.19 0.233 -1.147613 .2787623
Feb2013 .1377484 .2485647 0.55 0.579 -.3494295 .6249263
Mar2013 -.4705457 .3109241 -1.51 0.130 -1.079946 .1388543
Apr2013 -.1057625 .2890608 -0.37 0.714 -.6723112 .4607862
May2013 .2696423 .2374735 1.14 0.256 -.1957973 .7350818
Jun2013 .0301178 .2547631 0.12 0.906 -.4692086 .5294442
Jul2013 -.3757892 .3116575 -1.21 0.228 -.9866268 .2350483
Aug2013 -.7405637 .4171966 -1.78 0.076 -1.558254 .0771267
Sep2013 -.0693935 .3010278 -0.23 0.818 -.659397 .5206101
Oct2013 -.5504915 .3878986 -1.42 0.156 -1.310759 .2097759
Nov2013 -.0062395 .2900879 -0.02 0.983 -.5748013 .5623223
Dec2013 .0391461 .3151973 0.12 0.901 -.5786292 .6569214
_cons -2.028496 .0317162 -63.96 0.000 -2.090659 -1.966334
. testparm i.treatmonth
( 1) [_outcome]144.treatmonth = 0
( 2) [_outcome]145.treatmonth = 0
( 3) [_outcome]146.treatmonth = 0
( 4) [_outcome]147.treatmonth = 0
( 5) [_outcome]148.treatmonth = 0
( 6) [_outcome]149.treatmonth = 0
( 7) [_outcome]150.treatmonth = 0
( 8) [_outcome]151.treatmonth = 0
( 9) [_outcome]152.treatmonth = 0
(10) [_outcome]153.treatmonth = 0
(11) [_outcome]154.treatmonth = 0
(12) [_outcome]155.treatmonth = 0
(13) [_outcome]156.treatmonth = 0
chi2( 13) = 12.30
Prob > chi2 = 0.5030
. restore, preserve
. quietly keep if sample==2 & month>=43 // => adults
. eststo aWLS: regress prevalence month i.treatmonth [aw=observations]
(sum of wgt is 5.0666e+05)
Source SS df MS Number of obs = 114
F( 14, 99) = 31.69
Model .026115162 14 .001865369 Prob > F = 0.0000
Residual .005826866 99 .000058857 R-squared = 0.8176
Adj R-squared = 0.7918
Total .031942028 113 .000282673 Root MSE = .00767
prevalence Coef. Std. Err. t P>|t| [95% Conf. Interval]
month -.0004494 .0000259 -17.37 0.000 -.0005008 -.0003981
treatmonth
Dec2012 -.0163843 .0083749 -1.96 0.053 -.0330019 .0002333
Jan2013 -.0020348 .0083603 -0.24 0.808 -.0186234 .0145539
Feb2013 -.0011987 .0081781 -0.15 0.884 -.0174258 .0150283
Mar2013 .0029485 .0074825 0.39 0.694 -.0118984 .0177954
Apr2013 -.0086916 .0083848 -1.04 0.302 -.0253289 .0079457
May2013 .0053801 .0082912 0.65 0.518 -.0110713 .0218316
Jun2013 .0041807 .0076749 0.54 0.587 -.011048 .0194093
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Jul2013 -.0030649 .0081867 -0.37 0.709 -.0193091 .0131793
Aug2013 -.0041985 .0082814 -0.51 0.613 -.0206306 .0122335
Sep2013 .0001632 .0079553 0.02 0.984 -.0156218 .0159482
Oct2013 .0023396 .0088255 0.27 0.791 -.0151722 .0198513
Nov2013 -.0011681 .0078685 -0.15 0.882 -.0167809 .0144447
Dec2013 .0005878 .0093303 0.06 0.950 -.0179255 .0191012
_cons .2523039 .0024979 101.01 0.000 .2473475 .2572602
. testparm i.treatmonth
( 1) 144.treatmonth = 0
( 2) 145.treatmonth = 0
( 3) 146.treatmonth = 0
( 4) 147.treatmonth = 0
( 5) 148.treatmonth = 0
( 6) 149.treatmonth = 0
( 7) 150.treatmonth = 0
( 8) 151.treatmonth = 0
( 9) 152.treatmonth = 0
(10) 153.treatmonth = 0
(11) 154.treatmonth = 0
(12) 155.treatmonth = 0
(13) 156.treatmonth = 0
F( 13, 99) = 0.50
Prob > F = 0.9219
. eststo aLOG: blogit smokers observations month i.treatmonth
Logistic regression for grouped data Number of obs = 506657
LR chi2(14) = 706.98
Prob > chi2 = 0.0000
Log likelihood = -258768.87 Pseudo R2 = 0.0014
_outcome Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.0027059 .0001243 -21.76 0.000 -.0029496 -.0024622
treatmonth
Dec2012 -.1154462 .0433894 -2.66 0.008 -.2004879 -.0304044
Jan2013 -.0177622 .0420483 -0.42 0.673 -.1001754 .064651
Feb2013 -.0124954 .0410966 -0.30 0.761 -.0930432 .0680525
Mar2013 .0145005 .0373205 0.39 0.698 -.0586464 .0876474
Apr2013 -.063631 .0428737 -1.48 0.138 -.147662 .0203999
May2013 .0298738 .0412358 0.72 0.469 -.0509469 .1106946
Jun2013 .0218607 .0382867 0.57 0.568 -.0531798 .0969012
Jul2013 -.0264287 .041477 -0.64 0.524 -.1077223 .0548648
Aug2013 -.0344222 .0420938 -0.82 0.414 -.1169246 .0480803
Sep2013 -.005408 .0401065 -0.13 0.893 -.0840152 .0731992
Oct2013 .0087724 .0443499 0.20 0.843 -.0781519 .0956967
Nov2013 -.0149389 .0398428 -0.37 0.708 -.0930293 .0631516
Dec2013 -.0034587 .0471415 -0.07 0.942 -.0958544 .088937
_cons -1.072061 .0118411 -90.54 0.000 -1.095269 -1.048853
. testparm i.treatmonth
( 1) [_outcome]144.treatmonth = 0
( 2) [_outcome]145.treatmonth = 0
( 3) [_outcome]146.treatmonth = 0
( 4) [_outcome]147.treatmonth = 0
( 5) [_outcome]148.treatmonth = 0
( 6) [_outcome]149.treatmonth = 0
( 7) [_outcome]150.treatmonth = 0
( 8) [_outcome]151.treatmonth = 0
( 9) [_outcome]152.treatmonth = 0
(10) [_outcome]153.treatmonth = 0
(11) [_outcome]154.treatmonth = 0
(12) [_outcome]155.treatmonth = 0
(13) [_outcome]156.treatmonth = 0
chi2( 13) = 11.67
Prob > chi2 = 0.5549
. restore
. coefplot (mWLS), bylabel(Minors (WLS)) ///
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> || (aWLS), bylabel(Adults (WLS)) ///
> || (mLOG), bylabel(Minors (Logit)) ///
> || (aLOG), bylabel(Adults (Logit)) ///
> ||, keep(*.treatmonth) levels(95 90) vertical xlabel(,angle(45)) ///
> yline(0) ylab(, angle(hor)) yti(Prevalence) ///
> byopts(yrescale rows(2))
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The graph depicts the monthly treatment e↵ects by sample and estimation technique, in-
cluding 95% and 90% confidence intervals as thin and thick lines, respectively. The WLS
estimates closely resemble the results shown in Figure 5 in Kaul and Wolf (2014b) and Fig-
ures 6 and 8 in Kaul and Wolf (2014a). For minors we do not see any clear deviations from
the baseline trend,11 except maybe the negative deviation in August 2013 in the Logit model,
which is significant using a one-sided test at the 5% level. Consequently, the overall tests (the
“testparm” results) do not provide much evidence for systematic deviations (with p-values of
0.888 and 0.503). The overall tests for adults are similarly weak (with two-sided p-values of
0.922 and 0.555), although there is a significant e↵ect in December 2012 (with p-values of
.053 and .008). Yet, as indicated by the overall tests, it is not very surprising to see a signifi-
cant e↵ect among 13 monthly estimates (for example, using a 5% level, we would expect one
11The picture does not change much if a flat trend from November 2012 on is assumed, because the variability
in monthly estimates is much stronger than the slope of the trend (not shown).
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significant result per twenty test). It is thus hard to say whether the December 2012 e↵ect is
systematic. Such a conclusion could only be drawn if there had been a strong and well justified
prior expectation of a specific e↵ect in December 2012 only, but not in other months.
3.3 Power
As mentioned above, statistical power to detect a treatment e↵ect with the present data is likely
to be low. Below are some results of a power analysis. To generate the simulated data I follow
the procedure suggested by Kaul and Wolf (2014a,b). That is, the data in a single replication
are generated as
yt =  0 +  1 · t +  t + ✏tpnt
where t = 1, . . . , 156 is the index of the month (t = 43, . . . , 156 in case of adults), nt is the
sample size in month t, and  0 and  1 are the coe cient estimates from the pre-treatment
WLS fit (see Section 3.1). ✏t is a random error following a normal distribution with mean 0
and variance  2 · n, where n is the average sample size in the pre-treatment months and  2
is the mean squared error (i.e. the error variance estimate) of the pre-treatment WLS fit.12  t
is the treatment e↵ect defined as    · I[t > 143], where I[] is the index function (i.e. 0 in
pre-treatment months, 1 in treatment-period months) and   is varied from 0 to .02 in steps of
.0025 (corresponding to a reduction in smoking rates due to plain packaging between 0 and 2
percentage points). Using such a definition the treatment e↵ect is immediate and time-constant.
To alternatively model a situation in which the treatment e↵ect builds up gradually I also use
 t =  ( /13) · (t   143) · I[t > 143], again varying   from 0 to .02 in steps of .0025. Using
this definition the treatment e↵ect unfolds linearly, from   /13 in December 2012 to    in
December 2013.
In the power analysis I include the WLS models from Section 3.2.1 (immediate treatment-
e↵ect model; power is the proportion of replications in which the treatment dummy is negative
and significant), Section 3.2.3 (gradual treatment-e↵ect model; power is the proportion of repli-
cations in which the spline parameter is negative and significant), and Section 3.2.4 (monthly
12I slightly deviate from Kaul and Wolf (2014a,b) in the computation of the error variance in that I (implicitly)
divide by T   2 (where T is the number of months on which the pre-treatment WLS fit is based) to account for the
degree of freedom consumed by the slope parameter. The numbers provided by Kaul and Wolf (2014a,b) suggest
that they divided by T   1. The rest of the procedure is identical, despite the di↵erence in notation.
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treatment-e↵ects model; power is (a) the proportion of replications in which any of the monthly
dummies is negative and significant and (b) the proportion of replications in which the overall
test across all dummies is significant). All tests use a nominal significance level of 5%. Each
run of the simulation is repeated twice, once using two-sided tests and once using one-sided
tests (the overall test for monthly dummies is only included in the two-sided test setting). The
results, based on 10,000 replications, are as follows:
. set seed 5218716
. local reps 10000
. program define wlssim, rclass
1. syntax [, cons(real 0) slope(real 0) sigma(real 1) ///
> delta(real 0) twosided onesided gradual immediate ]
2. if "`onesided´"!="" local level .10
3. else local level .05
4. if "`gradual´"=="" local teff `delta´*treat
5. else local teff (`delta´/13)*(month-143)*treat
6. tempvar y
7. generate `y´ = `cons´ + `slope´*month - `teff´ ///
> + rnormal(0, `sigma´)/sqrt(observations)
8. regress `y´ month treat [aw=observations]
9. return scalar b1 = _b[treat]
10. test treat
11. return scalar p1 = (r(p)<`level´) & (_b[treat]<0)
12. regress `y´ month pmonth [aw=observations]
13. return scalar b2 = _b[pmonth]
14. test pmonth
15. return scalar p2 = (r(p)<`level´) & (_b[pmonth]<0)
16. regress `y´ month i.imonth [aw=observations]
17. local any 0
18. forv i = 144/156 {
19. test `i´.imonth
20. if (r(p)<`level´) & (_b[`i´.imonth]<0) local any 1
21. }
22. return scalar p3 = `any´
23. if "`onesided´"=="" {
24. testparm i.imonth
25. return scalar p4 = (r(p)<`level´)
26. }
27. end
. use tobacco
. drop if sample==2 & month<43
(42 observations deleted)
. generate byte treat = month>=144
. generate pmonth = cond(month>143, month-143, 0)
. generate imonth = cond(month>143, month, 0)
. capt mat drop wlssim
. forv s =1/2 {
2. local sti: word `s´ of minors adults
3. qui regress prevalence month if sample==`s´ & treat==0 [aw=observations]
4. su observation if sample==`s´ & treat==0, mean
5. local cons = _b[_cons]
6. local slope = _b[month]
7. local sigma = sqrt(r(mean)) * e(rmse)
8. preserve
9. foreach type in "immediate" "gradual" {
10. foreach test in twosided onesided {
11. local p4
12. if "`test´"=="twosided" local p4 "p4=r(p4)"
13. capt mat drop tmp
14. forv delta = 0(0.0025).02 {
15. qui keep if sample==`s´
16. qui simulate b1=r(b1) p1=r(p1) b2=r(b2) p2=r(p2) p3=r(p3) ///
> `p4´, reps(`reps´) : wlssim, cons(`cons´) slope(`slope´) ///
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> sigma(`sigma´) delta(`delta´) `test´ `type´
17. qui mean *
18. mat tmp = nullmat(tmp) \ ((`delta´), e(b))
19. restore, preserve
20. }
21. mat coleq tmp = "`sti´ - `type´ effect - `test´ tests"
22. mat wlssim = nullmat(wlssim) \ tmp´
23. }
24. }
25. restore, not
26. }
. estout matrix(wlssim, fmt(4)), coll(none) nolz varw(26) modelw(7) del("") noabbrev ml(none) ///
> drop(b*) varlab(c1 "effect size" p1 "- immediate effect model" p2 "- gradual effect model" ///
> p3 "- monthly effects: any" p4 "- monthly effects: overall") refcat(p1 "power", nolabel)
minors - immediate effect - twosided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0250 .0581 .1110 .2113 .3232 .4659 .6139 .7546 .8516
- gradual effect model .0270 .0502 .0920 .1629 .2449 .3502 .4671 .5954 .7123
- monthly effects: any .2634 .3386 .4220 .4983 .5861 .6690 .7446 .8219 .8688
- monthly effects: overall .0507 .0549 .0668 .0857 .1157 .1572 .2331 .3111 .4115
minors - immediate effect - onesided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0511 .1047 .1811 .2980 .4443 .5898 .7313 .8370 .9159
- gradual effect model .0491 .0921 .1537 .2455 .3536 .4750 .5998 .7044 .8133
- monthly effects: any .4703 .5524 .6323 .7165 .7907 .8438 .9035 .9351 .9659
minors - gradual effect - twosided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0273 .0385 .0620 .0868 .1128 .1650 .2099 .2702 .3272
- gradual effect model .0291 .0435 .0700 .1075 .1456 .2142 .2854 .3573 .4340
- monthly effects: any .2703 .3120 .3423 .3872 .4331 .4892 .5395 .5896 .6347
- monthly effects: overall .0530 .0526 .0567 .0634 .0687 .0804 .1016 .1293 .1536
minors - gradual effect - onesided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0525 .0728 .1078 .1411 .1959 .2461 .3196 .3921 .4652
- gradual effect model .0486 .0789 .1198 .1711 .2423 .3028 .4038 .4917 .5817
- monthly effects: any .4656 .5221 .5590 .6041 .6547 .7059 .7537 .7938 .8296
adults - immediate effect - twosided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0253 .1460 .4288 .7703 .9463 .9939 .9998 1.0000 1.0000
- gradual effect model .0241 .1132 .3129 .6043 .8334 .9523 .9906 .9993 1.0000
- monthly effects: any .2617 .4559 .6601 .8348 .9394 .9827 .9966 .9998 1.0000
- monthly effects: overall .0511 .0726 .1450 .3157 .5608 .8006 .9461 .9923 .9989
adults - immediate effect - onesided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0512 .2244 .5569 .8490 .9709 .9980 .9999 1.0000 1.0000
- gradual effect model .0485 .1818 .4303 .7154 .9049 .9786 .9959 .9997 .9999
- monthly effects: any .4659 .6694 .8352 .9470 .9843 .9985 .9997 .9999 1.0000
adults - gradual effect - twosided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0248 .0686 .1474 .2863 .4572 .6337 .7833 .8956 .9544
- gradual effect model .0260 .0817 .1950 .3883 .6096 .8027 .9170 .9729 .9942
- monthly effects: any .2661 .3668 .4717 .6134 .7309 .8320 .9176 .9608 .9856
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- monthly effects: overall .0490 .0565 .0775 .1321 .2228 .3329 .5045 .6671 .8090
adults - gradual effect - onesided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0512 .1227 .2431 .3995 .5869 .7490 .8666 .9424 .9781
- gradual effect model .0518 .1443 .3003 .5119 .7238 .8750 .9581 .9891 .9982
- monthly effects: any .4613 .5806 .6944 .7989 .8865 .9473 .9758 .9914 .9979
For the case with a zero treatment e↵ect we see that the type I error rates more or less match
the nominal rate for the immediate e↵ect model and the gradual e↵ect model, about 2.5% for
the two-sided tests (since only negative e↵ects are counted) and about 5% for the one-sided
tests (see first column of the tables in the output above). Also the overall test for the monthly
dummies model has the expected type I error rate of about 5%. The type I error rates of the test
whether any monthly dummy is significantly negative, however, are inflated due to multiple
testing (about 27% in the two-sided setting, and about 47% in the one-sided setting, instead
of the nominal 2.5% and 5%). That is, even in situations where there is no treatment e↵ect,
we would expect some monthly deviations that are significantly negative with considerable
likelihood. Consequently, such a test procedure also has high power for detecting existing
treatment e↵ects. For example, in case of an immediate one percentage point treatment e↵ect,
we would expect to see at least one significantly negative monthly deviation with a probability
of 59% (two-sided) or 78% (one-sided) for minors and 94% (two-sided) or 99% (one-sided)
for adults. Also for a gradual treatment e↵ect that reaches one percentage point by the end of
the observation period (which is harder to detect), power is relatively high, at least for adults
(44% and 66% for minors, 74% and 89% for adults, for the two-sided and one-sided tests,
respectively). Of course power is high because the error rate is inflated. Nonetheless we can
say that if there was a strong treatment e↵ect, such a test procedure would be quite likely to
pick it up.13
Naturally, the power of the tests that retain the nominal error rate is lower. If there is an
immediate treatment e↵ect of one percentage point, the power of the constant e↵ect model is
33% (two-sided) or 44% (one-sided) for minors and 94% (two-sided) or 97% (one-sided) for
adults. That is, power is still great for adults, but for minors we now already have a probability
13I consider a one percentage point di↵erence a strong treatment e↵ect (for minors, this is a 17% decrease in
smoking prevalence compared to the linear baseline trend in December 2013; for adults the corresponding decline
is 5.5%), but others might disagree. See the tables in the output above for power values for other e↵ect sizes.
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of a type II error (i.e. not do detect an existing e↵ect) of more than 50%. Moreover, power
reduces further if the e↵ect is gradual. In the setting with a gradual e↵ect that builds up to one
percentage point by December 2013, the gradual e↵ect model has a power of only 15% (two-
sided) or 24% (one-sided) for minors and 60% (two-sided) or 73% (one-sided) for adults. That
is, for minors it would be quite unlikely that such an e↵ect is detected, for adults the power
values are also below the conventional 80% level. Using a one-sided test with a conventional
5% significance level, an immediate treatment e↵ect would have to be close to 1.75 percent-
age points for minors, and about 0.75 percentage points for adults, to reach the conventional
80% power level; a gradual e↵ect would have to build up to more than 2 percentage points in
December 2013 for minors, and to about 1.25 percentage points for adults.14
The power simulations above might be criticized because they do not take into account that
error variances tend to decline the closer the prevalence gets to zero (a natural property of 0/1
variables). In the present context, this leads to underestimation of power. A data-generating
process that better matches the nature of the data should be based on the binomial distribution.
In the additional simulations below, I therefore generate the number of smokers in the monthly
samples as draws from binomial distribution B(nt, pt), where nt is the sample size in month t
and pt is the smoking probability. The smoking probability pt is modeled using the logistic
function
pt =
1
1 + e zt
with zt =  0 +  1 · t +  t + ut
where  0 and  1 are the Logit coe cients from the baseline trend and ut is is a random error
following a normal distribution with mean 0 and variance  2u. The values for  0,  1 and  u are
taken from a random-e↵ects logistic regression fitted to the pre-treatment observations, where
 u reflects the extra between-month variance in the data.15  t is defined as above, with the
value of   chosen such that a certain target percentage-point e↵ect is reached in December
2013 (again varying from 0 to 2 percentage points in steps of 0.25 percentage points). The
14Power at 2 percentage points is 58% for minors. Finding out how much stronger the e↵ect has to be to reach
the 80% level would require additional simulations.
15The variability of the prevalence estimates across months, net of the linear trend, is slightly higher than
one would expect from the binomial distribution alone. Power would be somewhat overestimated if this extra
variability was not taken into account
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same types of simulations and tests are performed as above, but now all tests are based on the
Logit model instead of the WLS model. The results are as follows:
. set seed 477350
. local reps 10000
. mata:
mata (type end to exit)
: real scalar getdelta(p, cons, slope)
> {
> rc = mm_root(x=., &myfun(), 0, 1, 0, 1000, p, cons, slope)
> if (rc) _error(499)
> return(x)
> }
: real scalar myfun(x, p, cons, slope)
> {
> return(p - (invlogit(cons + slope*156 - x) - invlogit(cons + slope * 156)))
> }
: end
. program define logitsim, rclass
1. syntax [, cons(real 0) slope(real 0) sigma(real 1) ///
> delta(real 0) twosided onesided gradual immediate ]
2. if "`onesided´"!="" local level .10
3. else local level .05
4. if "`gradual´"=="" local teff `delta´*treat
5. else local teff (`delta´/13)*(month-143)*treat
6. tempvar y
7. generate `y´ = rbinomial(observations, ///
> invlogit(`cons´ + `slope´*month - `teff´ + rnormal(0, `sigma´)))
8. blogit `y´ observations month treat
9. return scalar b1 = _b[treat]
10. test treat
11. return scalar p1 = (r(p)<`level´) & (_b[treat]<0)
12. blogit `y´ observations month pmonth
13. return scalar b2 = _b[pmonth]
14. test pmonth
15. return scalar p2 = (r(p)<`level´) & (_b[pmonth]<0)
16. blogit `y´ observations month i.imonth
17. local any 0
18. forv i = 144/156 {
19. test `i´.imonth
20. if (r(p)<`level´) & (_b[`i´.imonth]<0) local any 1
21. }
22. return scalar p3 = `any´
23. if "`onesided´"=="" {
24. testparm i.imonth
25. return scalar p4 = (r(p)<`level´)
26. }
27. end
. use tobacco
. drop if sample==2 & month<43
(42 observations deleted)
. generate byte treat = month>=144
. generate pmonth = cond(month>143, month-143, 0)
. generate imonth = cond(month>143, month, 0)
. capt mat drop logitsim
. forv s =1/2 {
2. local sti: word `s´ of minors adults
3. preserve
4. qui keep if treat==0 & sample==`s´
5. keep month observations prevalence
6. qui expand observations
7. sort month
8. by month: gen byte smokes = (_n<= round(observations*prevalence))
9. xtlogit smokes month, i(month)
10. local cons = _b[_cons]
11. local slope = _b[month]
12. local sigma = e(sigma_u)
33
13. restore, preserve
14. foreach type in "immediate" "gradual" {
15. foreach test in twosided onesided {
16. local p4
17. if "`test´"=="twosided" local p4 "p4=r(p4)"
18. capt mat drop tmp
19. forv delta = 0(0.0025).02 {
20. mata: st_local("d", strofreal(getdelta(-`delta´, `cons´, `slope´)))
21. qui keep if sample==`s´
22. qui simulate b1=r(b1) p1=r(p1) b2=r(b2) p2=r(p2) p3=r(p3) ///
> `p4´, reps(`reps´) : logitsim, cons(`cons´) slope(`slope´) ///
> sigma(`sigma´) delta(`d´) `test´ `type´
23. qui mean *
24. mat tmp = nullmat(tmp) \ ((`delta´), e(b))
25. restore, preserve
26. }
27. mat coleq tmp = "`sti´ - `type´ effect - `test´ tests"
28. mat logitsim = nullmat(logitsim) \ tmp´
29. }
30. }
31. restore, not
32. }
Fitting comparison model:
Iteration 0: log likelihood = -11757.613
Iteration 1: log likelihood = -11708.002
Iteration 2: log likelihood = -11707.726
Iteration 3: log likelihood = -11707.726
Fitting full model:
tau = 0.0 log likelihood = -11707.726
tau = 0.1 log likelihood = -11739.458
Iteration 0: log likelihood = -11739.461
Iteration 1: log likelihood = -11710.224
Iteration 2: log likelihood = -11707.679
Iteration 3: log likelihood = -11707.527
Iteration 4: log likelihood = -11707.52
Iteration 5: log likelihood = -11707.52
Random-effects logistic regression Number of obs = 38564
Group variable: month Number of groups = 143
Random effects u_i ˜ Gaussian Obs per group: min = 161
avg = 269.7
max = 381
Integration method: mvaghermite Integration points = 12
Wald chi2(1) = 90.64
Log likelihood = -11707.52 Prob > chi2 = 0.0000
smokes Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.004408 .000463 -9.52 0.000 -.0053154 -.0035005
_cons -2.029978 .0333685 -60.84 0.000 -2.095379 -1.964577
/lnsig2u -5.671567 1.649077 -8.9037 -2.439435
sigma_u .0586725 .0483778 .011657 .2953136
rho .0010453 .001722 .0000413 .0258241
Likelihood-ratio test of rho=0: chibar2(01) = 0.41 Prob >= chibar2 = 0.260
Fitting comparison model:
Iteration 0: log likelihood = -233896.9
Iteration 1: log likelihood = -233659.66
Iteration 2: log likelihood = -233659.53
Iteration 3: log likelihood = -233659.53
Fitting full model:
tau = 0.0 log likelihood = -233659.53
tau = 0.1 log likelihood = -234180.57
Iteration 0: log likelihood = -233805.85
Iteration 1: log likelihood = -233686.44 (not concave)
Iteration 2: log likelihood = -233663.19 (not concave)
Iteration 3: log likelihood = -233658.26 (not concave)
Iteration 4: log likelihood = -233655.37
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Iteration 5: log likelihood = -233654.19
Iteration 6: log likelihood = -233654.02
Iteration 7: log likelihood = -233654.02
Random-effects logistic regression Number of obs = 453961
Group variable: month Number of groups = 101
Random effects u_i ˜ Gaussian Obs per group: min = 4005
avg = 4494.7
max = 5126
Integration method: mvaghermite Integration points = 12
Wald chi2(1) = 305.26
Log likelihood = -233654.02 Prob > chi2 = 0.0000
smokes Coef. Std. Err. z P>|z| [95% Conf. Interval]
month -.0027056 .0001549 -17.47 0.000 -.0030091 -.0024021
_cons -1.07224 .0148719 -72.10 0.000 -1.101388 -1.043092
/lnsig2u -7.224383 .4008665 -8.010067 -6.438699
sigma_u .0269926 .0054102 .0182237 .0399811
rho .0002214 .0000887 .0001009 .0004856
Likelihood-ratio test of rho=0: chibar2(01) = 11.03 Prob >= chibar2 = 0.000
. estout matrix(logitsim, fmt(4)), coll(none) nolz varw(26) modelw(7) del("") noabbrev ml(none) ///
> drop(b*) varlab(c1 "effect size" p1 "- immediate effect model" p2 "- gradual effect model" ///
> p3 "- monthly effects: any" p4 "- monthly effects: overall") refcat(p1 "power", nolabel)
minors - immediate effect - twosided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0264 .0731 .1645 .3228 .5089 .7211 .8651 .9547 .9854
- gradual effect model .0276 .0618 .1280 .2395 .3934 .5720 .7307 .8750 .9460
- monthly effects: any .1992 .2635 .3452 .4435 .5481 .6592 .7513 .8583 .9166
- monthly effects: overall .0522 .0419 .0430 .0585 .0941 .1640 .2711 .4418 .6170
minors - immediate effect - onesided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0518 .1339 .2546 .4325 .6312 .8125 .9257 .9756 .9944
- gradual effect model .0504 .1154 .2027 .3480 .5192 .6966 .8341 .9261 .9744
- monthly effects: any .4184 .5306 .6300 .7310 .8111 .8903 .9432 .9721 .9896
minors - gradual effect - twosided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0269 .0461 .0780 .1204 .1820 .2535 .3518 .4757 .5951
- gradual effect model .0254 .0475 .0852 .1415 .2199 .3245 .4522 .6005 .7244
- monthly effects: any .2015 .2315 .2685 .3155 .3710 .4392 .4873 .5772 .6429
- monthly effects: overall .0547 .0485 .0414 .0471 .0531 .0685 .0830 .1198 .1745
minors - gradual effect - onesided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0497 .0844 .1348 .1964 .2706 .3716 .4846 .5898 .7096
- gradual effect model .0488 .0907 .1525 .2299 .3323 .4554 .5887 .7145 .8251
- monthly effects: any .4214 .4763 .5436 .5936 .6534 .7148 .7736 .8398 .8894
adults - immediate effect - twosided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0572 .2645 .6476 .9138 .9908 .9995 1.0000 1.0000 1.0000
- gradual effect model .0534 .2168 .5248 .8016 .9582 .9948 1.0000 1.0000 1.0000
- monthly effects: any .4731 .6981 .8838 .9706 .9950 .9997 .9999 1.0000 1.0000
- monthly effects: overall .2799 .3387 .5444 .7880 .9436 .9932 .9992 1.0000 1.0000
adults - immediate effect - onesided tests
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>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0915 .3629 .7370 .9492 .9969 1.0000 1.0000 1.0000 1.0000
- gradual effect model .0918 .3022 .6276 .8737 .9774 .9979 1.0000 1.0000 1.0000
- monthly effects: any .6679 .8496 .9567 .9911 .9995 1.0000 1.0000 1.0000 1.0000
adults - gradual effect - twosided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0549 .1360 .2762 .4772 .6890 .8404 .9379 .9815 .9960
- gradual effect model .0527 .1652 .3514 .6046 .8224 .9396 .9862 .9977 .9998
- monthly effects: any .4687 .6089 .7299 .8439 .9253 .9728 .9913 .9984 .9999
- monthly effects: overall .2756 .3054 .3748 .5149 .6712 .8155 .9167 .9761 .9956
adults - gradual effect - onesided tests
>
effect size .0000 .0025 .0050 .0075 .0100 .0125 .0150 .0175 .0200
power
- immediate effect model .0857 .2046 .3718 .5782 .7688 .8994 .9635 .9896 .9974
- gradual effect model .0857 .2344 .4616 .7029 .8789 .9668 .9933 .9988 1.0000
- monthly effects: any .6543 .7739 .8699 .9366 .9730 .9941 .9984 .9999 1.0000
We see that the power values are generally somewhat higher than in the WLS simulation,
but the overall picture is similar.16 I therefore refrain from a detailed discussion of these results.
However, Table 1 and Table 2 present a summary from both power simulations for minors and
adults, respectively, and also contain the results from Kaul and Wolf (2014a,b) and Laverty
et al. (forthcoming) for the purpose of comparison. From my simulations I include results
presuming an immediate e↵ect (columns labeled “Immediate”) and results presuming a gradual
e↵ect (columns labeled “Gradual”). For both cases results from the WLS model (based on the
first set of simulations) and from the Logit model (based on the second set of simulations)
are listed. Furthermore, I report the results for whether any monthly e↵ect is significantly
negative (column labeled “Any monthly e↵ect”) and for whether the treatment indicator from
the immediate e↵ect model (for the simulations presuming an immediate e↵ect) or the spline
parameter from the gradual e↵ect model (for the simulation presuming a gradual e↵ect) is
significantly negative (column “Treatment e↵ect model”). All results are based on one-sided
tests at a nominal significance level of 5 percent. I report the results from one-sided tests
16Curiously, the type I error rates in the adult sample are somewhat inflated. This seems to be due to peculiarities
of the data at hand, in particular, to the combined e↵ect of the extra variance in monthly prevalence estimates
(reflected in the ut error term) and the high variance in monthly sample sizes in the treatment period (see Figure 1
in Kaul and Wolf 2014a). If the extra variance term ut is omitted or if the simulation for adults is based on the
minors’ sample sizes, the simulated error rates match the nominal rates (results not shown). Probably, treating the
sample sizes as random instead of fixed in the simulations or using a random-e↵ects Logit for the tests would also
fix the problem.
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Table 1: Summary of power analyses for minors
E↵ect
size in
pct
points
Kaul&Wolf Any monthly e↵ect Treatment e↵ect model
Immediate Gradual Immediate Gradual
WLS Logit WLS Logit WLS Logit WLS Logit
0.00 47 42 47 42 5 5 5 5
0.25 58 55 53 52 48 10 13 8 9
0.50 67 63 63 56 54 18 25 12 15
0.75 75 72 73 60 59 30 43 17 23
1.00 83 79 81 65 65 44 63 24 33
1.25 88 84 89 71 71 59 81 30 46
1.50 93 90 94 75 77 73 93 40 59
1.75 94 97 79 84 84 98 49 71
2.00 97 99 83 89 92 99 58 83
Power in percent from one-sided tests at the 5% level; power values over 80% highlighted.
because we are interested in whether plain packaging decreases smoking prevalence. After
all, this is why plain packaging has been introduced. The choice of the test is not a matter of
whether an opposite e↵ect is possible or not. It rests on an a-priori decision to look only for
evidence for an e↵ect in one direction, which seems appropriate in the present context.
In Table 1 for minors we see that the power values computed by Kaul and Wolf (2014b,
Table 3), assuming an immediate e↵ect, could be replicated using the tests for whether any
monthly dummy is significantly negative. Power values reach 80% at about a treatment e↵ect
of 1 percentage point. Assuming a gradual e↵ect, however, the treatment e↵ect would have to
be about 1.75 percentage points by December 2013 for the tests to reach a power of 80%. As
mentioned before, these tests are problematic because they have an inflated error rate of around
45% due to multiple testing. Using tests that have the correct size (column “Treatment e↵ect
model”) we see that the treatment e↵ect would have to be larger than one percentage point
in any case for power to reach 80%, or considerably larger depending on whether the e↵ect
is immediate or gradual. From these results I conclude that, for minors, only a very strong
treatment e↵ect could be detected with these data with reasonable power.
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For adults, results look more favorable (Table 2). Again, assuming an immediate e↵ect, the
simulation results from Kaul and Wolf (2014a) could be qualitatively replicated.17 My results
from the tests whether any monthly e↵ect is significantly negative approximately match the
IM-2 and IM-3 results from Kaul and Wolf (2014a).18 Also if a gradual e↵ect is assumed,
power values from these tests are hight, reaching 80% at an e↵ect of 0.75 percentage points
(WLS) or 0.5 percentage points (Logit). But again, all these tests have an inflated type I error
rate of about 45 to 65 percent. That is, these tests are also quite likely to indicate an e↵ect
if there is, in fact, none. Looking at the tests that have approximately correct size (column
labeled “Treatment e↵ect model”) reveals that power values reach 80% at about a treatment
e↵ect of 0.75 percentage points if the e↵ect is immediate, and at about one percentage point
if the e↵ect is gradual. Hence, due to the larger sample size, smaller treatment e↵ects can be
detected with acceptable power for adults than for minors. Also note that a given percentage-
point treatment e↵ect corresponds to a smaller e↵ect for adults in relative terms than for minors,
because the smoking prevalence among adults is higher than among minors. From these results
I conclude that the chance of detecting an e↵ect for adults based on the given data would have
been reasonably high, if the e↵ect was around 1 percentage point or larger.
4 Remarks on the errors and issues raised by OxyRomandie
In the Annex to the letter of Mr. Diethelm from January 29, 2015, seven errors and seven issues
are listed. I will briefly address these errors and issues below. The titles of the errors and issues
are taken from the Annex.
4.1 Error #1: Erroneous and misleading reporting of study results
The argument is that there is a di↵erence between “no evidence for an e↵ect” and “evidence for
no e↵ect”. The distinction is due to the fact that a statistical test tries to find evidence against a
17I could not replicate the results from Laverty et al. (forthcoming). It is unclear to me how these power values
were computed and on which kind of test they are based.
18IM-1 is for the test whether the mean of the post-treatment residuals is significantly lower than the mean of
the last 12 pre-treatment residuals. IM-2 is for the test whether any monthly deviation is significantly negative.
IM-3 records whether IM-1 or IM-2 is significant. Since IM-2 is very likely to be significant if IM-1 is, the power
values of IM-2 and IM-3 are very similar.
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Table 2: Summary of power analyses for minors
E↵ect
size in
pct
points
Kaul&Wolf Laverty
et al.
Any monthly e↵ect Treatment e↵ect model
IM-1 IM-2 IM-3 Immediate Gradual Immediate Gradual
WLS Logit WLS Logit WLS Logit WLS Logit
0.00 47 67 46 65 5 9 5 9
0.25 20 64 67 11 67 85 58 77 22 36 14 23
0.50 45 82 85 22 84 96 69 87 56 74 30 46
0.75 72 93 96 37 95 99 80 94 85 95 51 70
1.00 91 98 99 55 98 >99 89 97 97 >99 72 88
1.25 >99 >99 95 99 >99 >99 88 97
Power in percent from one-sided tests at the 5% level; power values over 80% highlighted.
null hypothesis (the null hypothesis in the present context is that plain packaging has no e↵ect,
or a positive e↵ect, on smoking prevalence). If the test fails, this does not imply that the null
hypothesis is true. It only means that there was not su cient evidence to reject it (su cient
in the sense that there is a maximum a-priori probability, typically set to 5%, of falsely reject-
ing the null hypothesis). It may well be that there was simply not enough data to be able to
detect an existing e↵ect. OxyRomandie does not claim that Kaul and Wolf misrepresented the
results in their working papers. They accuse Kaul and Wolf of not having put enough e↵ort
into policing the use of their results by others (i.e. tobacco industry). I agree that some of the
quotes provided by OxyRomandie read as “evidence for no e↵ect” instead of “no evidence for
an e↵ect”. However: (1) The di↵erence between the two formulations is subtle and my ex-
perience is—based on teaching statistics—that people without statistical training are typically
not aware of the di↵erence. Of course, it is better to always use the correct formulation, but
I do not think that it really makes a big di↵erence (statistically trained people will appreciate
the correct meaning either way, while others will probably not understand the di↵erence). (2)
I am very skeptical of whether researchers can be held responsible for monitoring the use and
interpretation of their results by others. This would be an obligation that is impossible to fulfill
and it would strongly discourage researchers from publishing anything. Of course, we can ex-
pect researchers to pay attention to a correct representation of their results in press releases or
similar materials, if they are given the chance to do so. But we cannot make them responsible
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for what is published by others and we cannot expect them to actively watch out for material
misinterpreting their results.
4.2 Error #2: Power is obtained by sacrificing significance
OxyRomandie claims that the high power for detecting an existing e↵ect reported by Kaul
and Wolf (2014a,b) is due to an inflated type I error rate. This is certainly true, as the power
analyses above illustrate. However, this does not change the fact that the statistical procedure
used by Kaul and Wolf does have the power they claim it has (given their assumptions about
the nature and size of the e↵ect). It only means that their procedure also has a high probability
of falsely finding evidence for an e↵ect if there is none.
4.3 Error #3: Inadequate model for calculating power which introduces a bias towards
exceedingly large power values
OxyRomandie claims that the assumption of an immediate e↵ect, on which the power analyses
by Kaul and Wolf (2014a,b) are based, is unrealistic, and that it would be more realistic to
assume a gradual e↵ect. I do agree that a gradual e↵ect appears more realistic and that it is
more di cult to detect a gradual e↵ect. However, Kaul and Wolf (2014a,b) are very clear
about what their assumptions are and anyone is free to provide alternative analyses based on
other assumptions.
4.4 Error #4: Ignorance of the fact that disjunctive grouping of two tests results in a
significance level higher than the significance level of the individual tests
In their power analyses, Kaul and Wolf (2014a,b) combine two tests (whether the mean of the
treatment-period residuals is significantly lower than the mean of an an equal number of pre-
treatment residuals, and whether any monthly treatment-period residual is significantly nega-
tive). OxyRomandie claims that this combination of tests increases the significance level (i.e.
the type I error rate). This is true, although the e↵ect is not particularly strong in the present
case (because the two tests are not independent: the second test is very likely to be significant
if the first test is). However, again, this only means that there is an increased risk of finding an
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e↵ect if there is none. It does not render the power values reported by Kaul and Wolf (2014a,b)
invalid.
4.5 Error #5: Failure to take into account the di↵erence between pointwise and uniform
confidence intervals
This point addresses the problem that testing 13 (or 12) monthly deviations leads to high power
at the expense of an inflated type I error rate and that a global test that maintains the nominal
error rate (e.g. using uniform confidence intervals instead of pointwise confidence intervals)
has less power. Essentially, this is the same argument as in “Error #2” and “Error #4”. The
argument is undoubtedly true, but, again, it does not render the power values reported by Kaul
and Wolf (2014a,b) invalid.
4.6 Error #6: Invalid significance level due to confusion about one-tail vs. two- tail test
Kaul and Wolf (2014a) report tests for monthly deviations based on 90% confidence inter-
vals and based on 95% confidence intervals. OxyRomandie argues that watching for a 90%
confidence interval to be entirely negative is equivalent to a one-sided test at the nominal 5%
significance level. I agree. Kaul and Wolf (2014a), however, interpret their 90% confidence
interval approach as a two-sided test at the nominal 10% significance level. This is also cor-
rect, as long as both cases, an entirely negative confidence interval and an entirely positive
confidence interval are watched for. Therefore, the dispute is over whether a two-sided test
or a one-sided test is appropriate. Like OxyRomandie I consider a one-sided test appropriate
in the present context (see above), but it is essential to realize that there is no right or wrong
here. Whether to use a one-sided test or a two-sided test is an a-priori decision made by the
researchers. However, if the researchers decide to use a one-sided test they need to consistently
adhere to this decision regardless of the analysis’ results. That is, by deciding to do a one-sided
test for a negative e↵ect we restrict ourselves to find a negative e↵ect and forgo the possibility
to do detect a positive e↵ect. I think in the present context such a restriction is justifiable, but
others might disagree. In fact, Kaul and Wolf, in their reply to the Annex by OxyRomandie,
argue that we should not forgo this possibility.
However, note that the analyses performed by Kaul and Wolf are (mostly) in line with
a one-sided setting, not a two-sided setting. In particular, in their power simulations only
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significantly negative deviations are counted. Hence, the computed power values are valid for
one-sided tests at the 5% level, not for two-sided tests at the 10% level. The point is illustrated
by the fact that in my “two-sided” simulations above the type I error rates are around 2.5% and
not 5% (“immediate e↵ect model” and “gradual e↵ect model”). That is, the reported power
values are really power values for one-sided tests at the 2.5% and not power values for two-
sided tests at the 5% levels, as the tests only look for negative e↵ects. Only the results reported
for the overall test for monthly deviations are for two-sided tests at the 5% level. This may all
be somewhat confusing, but the bottomline is that indeed there is an inconsistency in Kaul and
Wolf (2014a): The power analyses they perform use one-sided tests, but their interpretation of
the December 2012 e↵ect is in terms of a two-sided test. For reasons of consistency, it would
be more appropriate to write something along the lines of “if we are willing to use a one-sided
test” instead of “if we are willing to accept a relatively low level of statistical significance”
(cf. abstract and conclusions in Kaul and Wolf 2014a). However, I would not consider this a
“fundamental flaw”.
4.7 Error #7: Invalid assumption of long term linearity
OxyRomandie argues that the assumption of a linear trend in the pre-treatment period is invalid
and evidence that there are some significant deviations from the linear trend is provided. From
my own analysis I cannot support the claim that a linear fit is inappropriate. There is some
extra variation in the monthly estimates in addition to what we would expect from a binomial
distribution, but the deviations appear unsystematic (i.e. not suggesting a specific alternative
longtime trend) and it would be di cult to come up with a convincing alternative trend model.
4.8 Issue #1: Avoiding evidence by post-hoc change to the method
OxyRomandie wonders why December 2012 was excluded from the set of treatment-period
months in the power simulations in Kaul and Wolf (2014a), while it was included in the power
simulations in Kaul and Wolf (2014b). I agree that it is odd to exclude December 2012, as plain
packaging came into e↵ect in December 2012. Excluding December 2012 from the power
simulations, however, is not critical (as can be seen in Table 2 above, comparing Kaul and
Wolf’s results with my results that include December 2012). I guess what Kaul and Wolf try to
say is: yes, we do find some evidence for an e↵ect in December 2012, but if there was a lasting
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e↵ect it should also show up in the remaining 12 months. The approach followed by Kaul and
Wolf (2014a) does appear a bit post-hoc, though.
4.9 Issue #2: Unnecessary technicality of the method, hiding the methodological flaws
of the papers
OxyRomandie claims that Algorithm 3.1 in Kaul and Wolf (2014a) could be simplified (eval-
uating whether a monthly estimate lies below the confidence interval around the trend line in-
stead of constructing a confidence interval around the monthly residual and evaluating whether
the upper bound is below zero). Obviously, the approach by Kaul and Wolf and the approach
by OxyRomandie are formally equivalent. Alternatively, we could also directly compute a
confidence interval around zero and see whether the residual lies below the lower bound. In
my analysis above I used yet a another (slightly di↵erent) approach, testing monthly dummies
against zero in a linear model. I do not consider the approach proposed by Kaul and Wolf
(2014a) particularly complicated. It is quite straightforward, as is the approach proposed by
OxyRomandie.
4.10 Issue #3: Very ine↵ective and crude analytic method
The Annex presents a graph from a power analysis showing that a “simple t-test” outperforms
Kaul and Wolf’s test strategy based on confidence intervals. It is entirely unclear to me what
kind of t-test the authors employ here, nor can I link the presented power values for Kaul and
Wolf’s approach back to the results published in the working papers by Kaul and Wolf.
Although I am puzzled about what OxyRomandie tries to illustrate here, I do agree that
better test approaches exist than the one used by Kaul and Wolf. However, it is not an issue of
lack of power, it is an issue of inflated type I error (see above).
4.11 Issue #4: Non standard, ad-hoc method
OxyRomandie accuses Kaul and Wolf of using analytic techniques “that are far from standard”
and that their power analyses require writing a “computer program”. I do not see the problem.
All steps taken by Kaul and Wolf are simple and transparent and their analyses are easy to
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replicate. No fancy tools are needed. Power analyses will always require a bit of programming
except for very basic problems for which canned solutions exist.
4.12 Issue #5: Contradiction and lack of transparency about the way data was obtained
Here OxyRomandie accuses Kaul and Wolf of providing unclear and inconsistent information
about how they acquired their data, and of falsely claiming that the data are “publicly available”.
It is not really clear to me what exactly OxyRomandie’s critique is. In their papers, Kaul and
Wolf write that the data are from Roy Morgan, that PMI (Philip Morris International) provided
funding, and that the data for adults were received through PMI, but not the data for minors.
My reading of this is that the data for minors were received directly from Roy Morgan.
OxyRomandie claims that the data are not “publicly available” because they have to be paid
for. My observation is that there are many “publicly available” dataset for which one has to sign
a data contract and pay a fee. Maybe, however, it is a question of how high the costs are, which
is unknown to me.
At a superficial level, if one wants to save the costs of buying the data, the analyses by Kaul
and Wolf can be replicated by reverse engineering the data from Figures 1 and 2 in their papers.
This will provide the raw data points that were used in their analyses. However, as mentioned
in Section 2 there is no information about how these data points were created from the original,
individual-level survey data. A full replication, ideally, would use these original datasets.
4.13 Issue #6: Conflict of interest not fully declared
OxyRomandie accuses Kaul and Wolf of not having been fully transparent about the role of
PMI. Kaul and Wolf did declare that PMI provided funding. In my opinion, this clearly iden-
tifies the papers as industry sponsored research. Whether PMI, by contract, had the possibility
to comment on the papers prior to planned publication or not, does not really appear essential
to me. Things might be di↵erent if the contract gave PMI a right of veto against publication
(which does not seem to be the case according to the quote from the contract presented by
OxyRomandie).
In general, the problem with industry sponsored research might not be so much that single
studies are biased or flawed. A much bigger problem, in my opinion, is that industry funding
biases the selection of studies that are conducted and that unfavorable results are often withheld,
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leading to publication bias. In the present case it does not seem that PMI could have withheld
publication if results would have been unfavorable, but we do not really know.
On a di↵erent note, one might be tempted to argue that tobacco industry fighting plain pack-
aging is an indirect proof for the e cacy of plain packaging to reduce smoking prevalence (why
bother, if it doesn’t do anything?). However, this is not necessarily true. First and foremost,
branding is an instrument to secure or increase market shares in a competitive market. It may
well be that certain measures do not a↵ect overall prevalence, but that they a↵ect which brands
people consume. Hence tobacco companies have an interest in being able to use the instrument
even if it has no e↵ect on overall prevalence. On the other hand, of course, declining overall
prevalence reduces the size of the company’s potential market.
4.14 Issue #7: Lack of peer review
OxyRomandie criticize that the working papers were published without having gone through
peer review. All I can say is that it is standard practice in economics to make results available
as a working paper before submission to a peer reviewed journal.
Whether Kaul andWolf assisted in an orchestrated campaign of tobacco industry to promote
the papers I cannot judge.
5 Conclusions
OxyRomandie requested the retraction of the two working papers by Kaul and Wolf from the
website of the University of Zurich. Generally speaking, I do not recommend retraction of
research papers that seem to be flawed. Science is based on information, this includes informa-
tion on things that went wrong. Retracting a paper deemed as flawed would remove an essential
piece of information. This is particularly relevant after a public debate has taken place.
Regarding the papers by Kaul and Wolf examined in this report, I come to the following
conclusions:
• Although I am not happy with all aspects of the papers (see, e.g., Section 2), I do not
think that the papers are fundamentally flawed from a methodological point of view. I
do not suggest their retraction. There is some space for improvement and some of the
interpretations by Kaul and Wolf might be challenged, but these are all issues that can
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be resolved through usual scientific discourse. Moreover, the studies provide enough
information about data, methods, and procedures to be replicable by other researchers.
• Due to the high relevance of the topic, however, it might be reasonable to add a note
(either on the website providing the working papers or directly within the working pa-
pers) stating that these studies have been discussed controversially (including reverences
to relevant documents).
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